| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/05/2001 | WO2001022999A1 Dermal or transdermal application system containing an iota carragheenate |
| 04/05/2001 | WO2001022998A1 Stable calcitriol solution for packaging in vials |
| 04/05/2001 | WO2001022997A1 Analgesics |
| 04/05/2001 | WO2001022990A2 Methods related to immunostimulatory nucleic acid-induced interferon |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001022982A2 Compositions for reducing sympathomimetic-induced side effects by serenoa repens extract |
| 04/05/2001 | WO2001022981A1 Treatment of diabetic nephropathy and microalbuminuria |
| 04/05/2001 | WO2001022980A1 Side effects treatment |
| 04/05/2001 | WO2001022979A1 Method to disrupt mitochondrial function |
| 04/05/2001 | WO2001022977A2 Echinacea supplement and method of manufacture |
| 04/05/2001 | WO2001022976A2 Combination of a statin and ex-vivo treated blood for treating artheroclerosis |
| 04/05/2001 | WO2001022974A1 Prevention of colorectal cancer |
| 04/05/2001 | WO2001022973A1 The use of a positively charged carbohydrate polymer for the prevention of infection |
| 04/05/2001 | WO2001022972A2 Immunostimulatory nucleic acids |
| 04/05/2001 | WO2001022971A1 Sebum production inhibitors |
| 04/05/2001 | WO2001022970A1 Therapy with 2-5a and interferon |
| 04/05/2001 | WO2001022969A2 Vasopressin agonist formulation and process |
| 04/05/2001 | WO2001022968A1 Anticancer agents |
| 04/05/2001 | WO2001022967A1 Compositions having improved stability |
| 04/05/2001 | WO2001022966A1 Caspases and apoptosis |
| 04/05/2001 | WO2001022963A1 Method of preventing osteoporosis |
| 04/05/2001 | WO2001022962A1 Anti-hypercholesterolemic drug combination |
| 04/05/2001 | WO2001022961A1 New use of modafinil and the d/l enantiomer |
| 04/05/2001 | WO2001022960A1 Treatment of carbon monoxide poisoning |
| 04/05/2001 | WO2001022959A2 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions |
| 04/05/2001 | WO2001022958A2 A pharmaceutical composition containing lycopene for stabilising atherosclerotic plaques |
| 04/05/2001 | WO2001022957A2 Use of gangliosides and other substances for modulating sphingolipid-cholesterol microdomains |
| 04/05/2001 | WO2001022956A2 NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS |
| 04/05/2001 | WO2001022954A2 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents |
| 04/05/2001 | WO2001022953A2 Use of retigabin for treating neuropathic pain |
| 04/05/2001 | WO2001022952A2 Use of tace inhibitors |
| 04/05/2001 | WO2001022951A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 04/05/2001 | WO2001022950A2 Diosolane nucleoside analogs for the treatment or prevention of viral infection |
| 04/05/2001 | WO2001022949A2 Use of alprostadil (prostaglandin e1) for producing a medicament for angioneogenesis |
| 04/05/2001 | WO2001022945A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | WO2001022944A1 Oral controlled release formulations |
| 04/05/2001 | WO2001022941A1 Melt granulated composition and modified release dosage form prepared from said composition |
| 04/05/2001 | WO2001022940A1 Sustained release matrix systems for highly soluble drugs |
| 04/05/2001 | WO2001022938A1 Antiviral compositions |
| 04/05/2001 | WO2001022937A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | WO2001022936A1 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 04/05/2001 | WO2001022935A1 Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same |
| 04/05/2001 | WO2001022923A2 Scar treatment composition |
| 04/05/2001 | WO2001022917A2 Effervescent compositions comprising nimesulide |
| 04/05/2001 | WO2001022907A1 Drug delivery of phase changing formulation |
| 04/05/2001 | WO2001022837A1 Composition comprising casein protein and whey protein |
| 04/05/2001 | WO2001022820A1 Use of pramipexole as a treatment for cocaine craving |
| 04/05/2001 | WO2001022791A2 Controlled release compositions comprising nimesulide |
| 04/05/2001 | WO2001012602A8 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 04/05/2001 | WO2001011369A8 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 04/05/2001 | WO2001006015A8 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 04/05/2001 | WO2001005397A8 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 04/05/2001 | WO2000072820A3 Injectable anesthetic formulation |
| 04/05/2001 | WO2000069440A3 Nicotine delivery systems |
| 04/05/2001 | WO2000068198A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 04/05/2001 | WO2000066752A3 Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide |
| 04/05/2001 | WO2000066580A3 Antifungal ethers |
| 04/05/2001 | WO2000066126A3 Liposome compositions for improved drug retention |
| 04/05/2001 | WO2000066103A3 Contraceptive compositions containing cyclic urea and amide derivatives |
| 04/05/2001 | WO2000061139A8 Anticonvulsant derivatives useful in reducing blood glucose levels |
| 04/05/2001 | WO2000057877A8 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 04/05/2001 | WO2000057863A3 Use of pyridoxine compounds for treatment of cardiovascular and related pathologies |
| 04/05/2001 | WO2000057860A3 Peroxovanadium compounds as antineoplastic agents for the treatment of cancer |
| 04/05/2001 | WO2000056736A3 Use of non-nucleoside reverse transcriptase inhibitor (mni) for the treatment of hiv infection |
| 04/05/2001 | WO2000056292A3 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine |
| 04/05/2001 | WO2000053013A8 Inhibition of pkc to treat permeability failure |
| 04/05/2001 | WO2000052205A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 04/05/2001 | WO2000051581A3 Hydroxy-halo-quinazolines for augmentation of mast cell bactericidal activity |
| 04/05/2001 | WO2000051547A3 Inhibitors of prenyl-protein transferase |
| 04/05/2001 | WO2000050398A3 Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| 04/05/2001 | WO2000050090A3 Dry acid-chitosan complexes |
| 04/05/2001 | WO2000050023A8 Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases |
| 04/05/2001 | WO2000047197A3 Alkylating agents for treatment of cellular proliferation |
| 04/05/2001 | WO2000045803A3 Use of 5-aminosalicylates as antimicrobial agents |
| 04/05/2001 | WO2000044362A3 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 04/05/2001 | WO2000040228A3 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 04/05/2001 | WO2000020450A9 Calcium channel alpha-2/delta gene |
| 04/05/2001 | WO2000015036A9 Topical dermal antimicrobial compositions |
| 04/05/2001 | WO2000009120A8 New use of taxoid derivatives |
| 04/05/2001 | WO1996018391B1 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| 04/05/2001 | US20010000179 Inhibitors of typsin-like serine protease; anticoagulants |
| 04/05/2001 | US20010000151 Growing Thraustochytrium, Schizochytrium, and/or mixtures in a culture medium containing a non-chloride sodium salt, e.g., sodium sulfate; microfloral biomass; aquaculture of larval shrimp, rotifers, molluscs; extruded food with flaxseed meal |
| 04/05/2001 | US20010000143 Using dimethyl ether and elevated temperature/pressure to dissolve the solid; releasing the pressure to precipitate the fine powder and expand the ether into a gas; drugs; vitamins; carotenoid, especially beta-carotene; foods; cosmetics |
| 04/05/2001 | DE19947457A1 New 2'-aminomethyl-biphenyl-2-carboxamide derivatives, are potassium channel blockers especially useful for treating re-entry or supraventricular arrhythmia or atrial fibrillation or flutter |
| 04/05/2001 | DE19947440A1 1-Aziridino-1-hydroxyiminomethyl-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel 1-Aziridino-1-hydroxyiminomethyl derivatives, processes for their preparation and medicaments containing these compounds |
| 04/05/2001 | DE19947235A1 Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten New combination of loteprednol and beta¶2¶-adrenoceptor agonists |
| 04/05/2001 | DE19947234A1 Neue Kombination von Loteprednol und Antihistaminika New combination of loteprednol and antihistamines |
| 04/05/2001 | DE19945522A1 Pharmazeutisches, wirkstoffhaltiges Gel A pharmaceutical gel containing active ingredients |
| 04/05/2001 | DE19945484A1 NO-freisetzende topisch applizierbare Zusammensetzung NO-releasing topically administrable composition |
| 04/05/2001 | CA2811455A1 Highly conserved genes and their use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical microorganisms from clinical specimens for diagnosis |
| 04/05/2001 | CA2659048A1 Use of retigabine for the treatment of neuropathic pain |
| 04/05/2001 | CA2657208A1 Method of treating inflammatory conditions with progesterone of progesterone analogs |
| 04/05/2001 | CA2640998A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | CA2388474A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | CA2388461A1 Highly conserved genes and their use to generate probes and primers for the detection of microorganisms |
| 04/05/2001 | CA2388438A1 Stable calcitriol solution for packaging in vials |
| 04/05/2001 | CA2388055A1 Immunostimulatory nucleic acids |
| 04/05/2001 | CA2388025A1 Therapy with 2-5a and interferon |
| 04/05/2001 | CA2386095A1 Therapeutic treatment of androgen receptor driven conditions |
| 04/05/2001 | CA2386092A1 Piperidine derivatives |